Report ID: SQMIG35A2514
Report ID:
SQMIG35A2514 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|
Tables:
62 |
Figures:
75
In February 2024, Crohn’s Colitis Cure (CCCure) declared the enrollment of its debut subscription member to its premier inflammatory bowel disease (IBD) clinical management system, Crohn’s Colitis Care (CCCare). This membership grants access to an extensive database of real-time IBD patient and clinical data, alongside comprehensive analytics, making it the largest resource globally.
In October 2023, UCB, a leading global biopharmaceutical company, declared that the U.S. Food and Drug Administration (FDA) has approved BIMZELX® to treat moderate to severe plaque psoriasis in adults eligible for systemic therapy or phototherapy.
In September 2023, a recent report revealed a concerning trend regarding the rising prevalence and incidence of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, in Canada. Conducted by the Canadian Gastro-Intestinal Epidemiology Consortium across six provinces indicates a significant increase in IBD prevalence since 2002. Initially recorded at 400 cases per 100,000 individuals in 2002, the prevalence increased to 636 cases per 100,000 by 2014.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35A2514